Document |
Document Title |
WO/2001/087888A1 |
This invention relates to a series of pyrazolopyrimidinone derivatives, having an excellent inhibiting activity against cyclic guanosine 3',5'- monophosphate specific phosphodiesterase (cGMP specific PDE; PDE V), process for their prepar...
|
WO/2001/083438A2 |
New RAR selective retinoid agonists of formula (I) wherein the symbols are as defined in the specification, and pharmaceutically active salts of carboxylic acids of formula (I), further the invention relates to the use of such retinoic a...
|
WO/2001/074753A1 |
The invention relates to lunularic acid derivatives which are suitable as chemopreventive agents.
|
WO/2001/070663A2 |
This invention relates to novel aldehyde containing compounds and their uses as adjuvants and immunoeffectors.
|
WO/2001/056968A1 |
A cyclic compound comprising m units of formula (Ia) and n units of formula (Ib) joined together to form a ring, wherein Y and Y?2¿ are divalent bridging groups which may be the same or different in each unit; R?0¿ is H or (C¿1?-C¿6?...
|
WO/2001/055085A1 |
The present invention relates to compounds of general formula (I). The compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PP...
|
WO/2001/046130A1 |
A process for producing fomesafen from acifluorfen comprises the steps of (a) converting acifluorfen to its acid chloride, (b) coupling the acid chloride so formed with methanesulphonamide to form crude fomesafen and (c) purifying the cr...
|
WO2000001653A9 |
Processes are provided for the electrodialysis of a (di)alkali metal salt of an aromatic hydroxycarboxylic acid to produce a free aromatic hydroxycarboxylic acid and the alkali metal hydroxide, in the presence of a selected alkali metal ...
|
WO/2001/044155A1 |
A cyclic compound comprising m units of formula Ia and n units of formula (Ib) joined together to form a ring, wherein Y is a divalent bridging group which may be the same or different in each unit; R?0¿ is H, a C¿1?-C¿6? alkyl or a m...
|
WO1999024394A9 |
Amyloid binding compounds which are derivatives of Chrysamine G, pharmaceutical compositions containing, and methods using such compounds to identify Alzheimer's brain in vivo and to diagnose other pathological conditions characterized b...
|
WO/2001/036351A2 |
Compounds and pharmaceutical compositions useful as plasminogen activator inhibitor (PAI) antagonists are provided. In particular, methods of antagonizing PAI with substituted and unsubstituted aryl and heteroaryl ethers and thioethers, ...
|
WO/2001/032596A1 |
Phenoxy carboxylic acid compounds and compositions for the delivery of active agents are provided. Methods of administration and preparation are provided as well.
|
WO/2001/032130A2 |
Phenyl amine carboxylic acid compounds and compositions for the delivery of active agents are provided. Methods of administration and preparation are provided as well.
|
WO/2001/030737A1 |
Granules of 2-hydroxynaphthalene-3-carboxylic acid, characterized as having an average particle diameter of 150 $g(m)m or more and a hardness of 70g to 3000g; and a method for preparing said granules, characterized as comprising subjecti...
|
WO/2001/030736A2 |
The present invention relates to new aromatic di-keto derivatives and to their pharmaceutically acceptable salts, esters, ethers and other obvious chemical equivalents. The derivatives are glucose-6-phosphate translocase inhibitors and c...
|
WO/2001/019778A1 |
The invention relates to the use of compounds of formula (I) and of their salts and stereoisomers in the production of medicaments for treating cardiovascular diseases.
|
WO/2001/019776A2 |
The invention relates to compounds of formula (I) as well as the salts and stereoisomers thereof used to produce medicaments for the treatment of cardiovascular diseases.
|
WO/2001/014334A1 |
Neuroprotective drugs are disclosed which are analogs of certain previously known fluorenone compounds. The new analogs have structure (I), where X is a lower alkyl, substituted alkyl, or cycloalkyl group, R is selected from certain type...
|
WO/2001/005797A1 |
The invention concerns compounds derived from titanium of formula [TiF¿x?L¿y?]?z-¿ wherein L represents a compound of formula (II): wherein m is 0 or 1 and n is 0, 1 or 2, and x represents 2, 4 or 5, y represents 1 or 2 and z represen...
|
WO/2000/068178A1 |
Novel compounds which are compounds represented by general formula (1) or salts thereof. They are useful as a component of a polyester, polyamide, etc. When the compounds wherein Y¿1?, Y¿2?, Y¿3?, and/or Y¿4? is carboxyl are used esp...
|
WO/2000/068177A1 |
A crystal of 2-hydroxynaphthalene-3-carboxylic acid (BON), characterized in that the mean particle diameter is 157 $g(m)m or above and the content of particles having diameters of 74 $g(m)m or below is 14 % or below. This crystal can be ...
|
WO/2000/066522A1 |
The present invention provides non-steroidal compounds of formula (I) which are selective modulators (i.e., agonists and antagonists) of a steroid receptor, specifically, the glucocorticoid receptor. The present invention also provides p...
|
WO/2000/064888A1 |
This invention is directed to diaryl acid derivatives of formula (I) and their pharmaceutical compositions as PPAR ligand receptor binders. The PPAR ligand receptor binders of this invention are useful as agonists or antagonists of the P...
|
WO/2000/064876A1 |
This invention is directed to triaryl acid derivatives of formula (I) and their pharmaceutical compositions as PPAR ligand receptor binders. The PPAR ligand receptor binders of this invention are useful as agonists or antagonists of the ...
|
WO/2000/059861A1 |
Certain novel substituted (5,6)-dihydronaphthalenyl and substituted (5,6,7,8)-tetrahydronaphthalenyl compounds selectively activate Retinoid X Receptors (RXRs) and are useful in various dermatological diseases, in the treatment of malign...
|
WO/2000/059875A2 |
Derivatives of aryl and heterocyclic ureido and aryl and heterocyclic carboxamido phenoxy isobutyric acids have been found to inhibit the nonenzymatic glycation of proteins which often results in formation of advanced glycation endproduc...
|
WO/2000/058258A1 |
Compounds which are useful in the efficient synthesis of 2-amino-4-oxobicyclo[3.1.0]hexane-2,6-dicarboxylic acid. The compounds are 2-oxobicyclo[3.1.0]hexane-6-carboxylic acid derivatives represented by formula (1) [wherein R?1¿ represe...
|
WO/2000/050375A1 |
The invention relates to a method for producing [1,1':4',1']-terphenyl compounds of formula (1), wherein R is hydrogen or a (C¿1?-C¿4?) alkyl radical, R?1¿ represents hydrogen, a (C¿1?-C¿4?) alkyl radical or a (C¿1?-C¿4?) alkoxy r...
|
WO/2000/031015A1 |
The invention provides a process for modifying CNSL comprising subjecting the CNSL to ozonolysis to form ozonolysis reaction products followed by reduction of the ozonolysis reaction products to give a mixture of phenolic components and ...
|
WO/2000/027792A1 |
Compounds represented by formula (I) wherein N¿1? represents an atom to which a donor hydrogen atom in a hydrogen bond donor group is bonded or a hydrogen bond acceptor atom in a hydrogen bond acceptor group; N¿3? represents a hydrogen...
|
WO/2000/023413A1 |
The invention relates to a method for drying phenoxymethylbenzoic acids of general formula (I), whereby X, Y, m and n have the following meanings: X, Y represent halogen or a C-organic radical, m represents a value ranging from 0 to 4 an...
|
WO/2000/023526A1 |
A toning agent for azo pigments, a toned azo pigment, and a process for producing the same. 2-Hydroxynaphthalene-3,6-dicarboxylic acid and a derivative thereof are incorporated into a main coupler ingredient for an azo pigment. The resul...
|
WO/2000/017147A1 |
The 5,6-dihydronaphthalenyl derivatives of the formulae (I) and (II) possess potent retinoid-like activity against dermatological diseases with a substantially reduced irritancy profile when administered topically.
|
WO/2000/015214A1 |
This invention relates to a pharmaceutical composition comprising a Fc receptor modulating compound and a pharmaceutically acceptable carrier. The present invention also relates to a method for treating a variety of diseases using a Fc r...
|
WO/2000/007972A1 |
Novel glucocorticoid and thyroid receptor ligands as provided which have the general formula (I) in which: R¿1? is an aliphatic hydrocarbon, an aromatic hydrocarbon, carboxylic acid or ester thereof, alkenyl carboxylic acid or ester the...
|
WO/2000/006529A1 |
Diketoacids of Formula (A) are useful as inhibitors of viral polymerases. In particular hepatitis C virus RNA dependent RNA polymerase (HCV RdRp), hepatitis B virus polymerase (HBV pol) and reverse transcriptase of human immunodeficiency...
|
WO/2000/002455A1 |
Hypericin has been shown to specifically inhibit T-type calcium channel activity. $i(Hypericum) extract containing hypericin also inhibits T-type calcium channel activity. Moreover, other chemicals in $i(Hypericum) extract showed a syner...
|
WO/2000/001662A1 |
Non-hygroscopic salts of L-carnitine and of the lower alkanoyl L-carnitines with pamoic acid are described, which lend themselves favourably to the preparation of solid compositions suitable for oral administration. Solid compositions co...
|
WO/1999/059941A1 |
The invention concerns a method for orthometalation of a carbocyclic aromatic derivative bearing at least an electron donor group, characterised in that it consists in reacting said carbocyclic aromatic derivative with an efficient amoun...
|
WO/1999/058487A1 |
The present invention provides novel compounds of general formula (I), wherein R?1¿, R?2¿, W, Z and R?5¿ to R?10¿ are defined more fully in the description. The compounds are useful in the treatment of ailments and disorders where a ...
|
WO/1999/058486A1 |
The present invention provides novel compounds of general formula (I) wherein R?1¿, R?2¿, W, Z and R?5¿ to R?9¿ are defined more fully in the description. The compounds are useful in the treatment of ailments and disorders where a re...
|
WO/1999/052841A1 |
A process for producing aromatic compounds or polymers thereof from a plant body within a short period of time by a convenient procedure. More particularly, a plant body is treated with supercritical water or subcritical water to thereby...
|
WO/1999/043636A2 |
Disubstituted lavendustin A analogs that are PTK inhibitors having antiproliferative activity are described. Preferred compounds of the present invention, without limitation, satisfy either Formula (1) or Formula (2). Currently preferred...
|
WO/1999/036384A1 |
Alkenyldiarylmethane (ADAM) compounds have been found effective as anti-HIV agents. Novel ADAM compounds, their pharmaceutical formulations and a method of using same to treat viral infections are described.
|
WO/1999/035117A1 |
The subject invention involves processes for making 2,4-difluoro-3-Q1-benzoic acid, wherein Q1 is derived from an electrophilic reagent, comprising the steps of: (a) treating 1-bromo-2,4-difluorobenzene with a strong, non-nucleophilic ba...
|
WO/1999/033821A1 |
2,2-Dialkyl- 4-aryl-substituted benzopyran and benzothiopyran derivatives of formula (I) where the symbols have the meaning described in the specification, have retinoid negative hormone and/or antagonist-like biological activities. The ...
|
WO/1999/029706A2 |
The present invention discloses medicaments that are selectin-ligand structural mimetics that bind to certain selectins wherein the mimetics may lack the sialic acid and/or fucose of the natural selecting ligand, sialyl Lewis?x¿ (sLe?xÂ...
|
WO/1999/028284A1 |
The invention referres to dibenzosuberone derivatives and to the procedures of their preparation. According to this invention, conditions for a regioselective bromination of dibenzosuberone have been found, as well as for the isolation o...
|
WO/1999/027005A2 |
An oxygen scavenging agent and compositions capable of providing good oxygen absorption capabilities which contain said agent, wherein the agent is a modified anionic hydrotalcite particulate material.
|
WO/1999/025677A1 |
This invention relates to a cyclic compound comprising m units of formula (Ia) and n units of formula (Ib) joined together to form a ring, wherein each Y is a divalent bridging group which may be the same or different in each unit; R?0¿...
|